CN102762224A - 疫苗组合物 - Google Patents

疫苗组合物 Download PDF

Info

Publication number
CN102762224A
CN102762224A CN2010800584328A CN201080058432A CN102762224A CN 102762224 A CN102762224 A CN 102762224A CN 2010800584328 A CN2010800584328 A CN 2010800584328A CN 201080058432 A CN201080058432 A CN 201080058432A CN 102762224 A CN102762224 A CN 102762224A
Authority
CN
China
Prior art keywords
klh
compositions
peptide
concentration
egfrviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800584328A
Other languages
English (en)
Chinese (zh)
Inventor
S·S·阿梅德
J·J·巴克利三世
L·M·勒维斯
B·R·奥斯伯尔内
S·辛哈
J·M·索恩
F·扎曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Inc
Original Assignee
Celldex Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celldex Therapeutics Inc filed Critical Celldex Therapeutics Inc
Priority to CN201611022843.7A priority Critical patent/CN107412754A/zh
Publication of CN102762224A publication Critical patent/CN102762224A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2010800584328A 2009-12-22 2010-12-08 疫苗组合物 Pending CN102762224A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611022843.7A CN107412754A (zh) 2009-12-22 2010-12-08 疫苗组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28908309P 2009-12-22 2009-12-22
US61/289,083 2009-12-22
PCT/IB2010/055674 WO2011077309A2 (en) 2009-12-22 2010-12-08 Vaccine compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611022843.7A Division CN107412754A (zh) 2009-12-22 2010-12-08 疫苗组合物

Publications (1)

Publication Number Publication Date
CN102762224A true CN102762224A (zh) 2012-10-31

Family

ID=43797591

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800584328A Pending CN102762224A (zh) 2009-12-22 2010-12-08 疫苗组合物
CN201611022843.7A Pending CN107412754A (zh) 2009-12-22 2010-12-08 疫苗组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201611022843.7A Pending CN107412754A (zh) 2009-12-22 2010-12-08 疫苗组合物

Country Status (13)

Country Link
US (3) US20130034573A1 (https=)
EP (2) EP2515934B1 (https=)
JP (2) JP6007105B2 (https=)
KR (1) KR20120120185A (https=)
CN (2) CN102762224A (https=)
AU (1) AU2010334428B2 (https=)
CA (1) CA2785585A1 (https=)
IL (1) IL220308A0 (https=)
MX (1) MX337070B (https=)
NZ (2) NZ629256A (https=)
RU (1) RU2581020C2 (https=)
SG (2) SG181628A1 (https=)
WO (1) WO2011077309A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073982A (zh) * 2013-03-20 2015-11-18 致优制药有限公司 新型韩国国内猪繁殖与呼吸综合征病毒

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2536399T (pt) * 2010-02-21 2020-02-06 Bayer Healthcare Llc Método para ativação e conjugação de biomoléculas
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
KR20210027493A (ko) * 2018-07-19 2021-03-10 주식회사 헬릭스미스 네이키드 dna 유전자 요법을 위한 동결 건조된 약제학적 조성물
US20220273755A1 (en) * 2019-11-21 2022-09-01 Multiple Fortune Holding Limited Pharmaceutical composition, use and method for applying ganoderma microsporum immunomodulatory protein and keyhole limpet hemocyanin in carcinoma treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
CN1638798A (zh) * 2002-02-14 2005-07-13 中外制药株式会社 包含抗体的溶液制剂
CN101594877A (zh) * 2005-11-02 2009-12-02 杜克大学 同时的化学疗法和免疫疗法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH600453A5 (https=) 1976-12-30 1978-06-15 Autelca Ag
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
EP0491007B1 (en) * 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
CA2138997C (en) 1992-06-25 2003-06-03 Jean-Paul Prieels Vaccine composition containing adjuvants
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
EP1167379A3 (en) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1996016988A1 (en) * 1994-11-28 1996-06-06 Thomas Jefferson University Reagents and processes for targeting mutant epidermal growth factor receptors
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
DK1005368T3 (da) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
EP1003850B1 (en) 1997-06-06 2009-05-27 The Regents of the University of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2214722T3 (es) * 1997-07-31 2004-09-16 Metra Biosystems, Inc. Metodo de ensayo de peptidos de colageno.
ATE421527T1 (de) * 1997-08-27 2009-02-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkus b epitopen
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
TW570805B (en) * 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
ES2572834T3 (es) 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
ATE459373T1 (de) 1999-03-19 2010-03-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
JP2001163801A (ja) * 1999-04-02 2001-06-19 Oriental Yeast Co Ltd 乾燥ｃ反応性タンパク質組成物
PT1187629E (pt) 1999-04-19 2005-02-28 Glaxosmithkline Biolog Sa Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
TR200200777T2 (tr) 1999-09-24 2002-09-23 Smithkline Beecham Biologicals S.A. Polioksietilen alkil eteri veya esteriyle en az bir iyonik olmayan yüzey aktif maddeli adjuvant.
JP4393382B2 (ja) * 2002-08-14 2010-01-06 三菱化学株式会社 中枢性タウ蛋白質特異的抗体
JP4504098B2 (ja) * 2003-05-28 2010-07-14 武田薬品工業株式会社 抗体およびその用途
KR20130065723A (ko) * 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
ATE530165T1 (de) * 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
US20060287263A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing antigen-specific immune responses
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
US7887811B2 (en) * 2005-05-24 2011-02-15 Neovacs Method for preparing a stable immunogenic product comprising antigenic heterocomplexes of TNFα and a carrier protein
JP2010536341A (ja) * 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド 生物学的に活性なポリペプチドの特性を改変するための組成物および方法
SG187410A1 (en) * 2007-12-28 2013-02-28 Baxter Int Recombinant vwf formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
CN1638798A (zh) * 2002-02-14 2005-07-13 中外制药株式会社 包含抗体的溶液制剂
CN101594877A (zh) * 2005-11-02 2009-12-02 杜克大学 同时的化学疗法和免疫疗法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105073982A (zh) * 2013-03-20 2015-11-18 致优制药有限公司 新型韩国国内猪繁殖与呼吸综合征病毒

Also Published As

Publication number Publication date
MX2012007283A (es) 2012-07-30
EP3257525A2 (en) 2017-12-20
IL220308A0 (en) 2012-07-31
US20150087815A1 (en) 2015-03-26
WO2011077309A3 (en) 2011-10-06
SG10201408505SA (en) 2015-02-27
RU2012131162A (ru) 2014-01-27
AU2010334428B2 (en) 2015-05-21
SG181628A1 (en) 2012-07-30
US20190365886A1 (en) 2019-12-05
KR20120120185A (ko) 2012-11-01
US20130034573A1 (en) 2013-02-07
NZ629256A (en) 2016-02-26
EP2515934B1 (en) 2017-05-17
JP6007105B2 (ja) 2016-10-12
JP2013515049A (ja) 2013-05-02
EP3257525A3 (en) 2018-02-28
EP2515934A2 (en) 2012-10-31
AU2010334428A1 (en) 2012-07-05
WO2011077309A2 (en) 2011-06-30
JP6146927B2 (ja) 2017-06-14
CN107412754A (zh) 2017-12-01
MX337070B (es) 2016-02-11
JP2015180667A (ja) 2015-10-15
NZ600978A (en) 2014-08-29
CA2785585A1 (en) 2011-06-30
RU2581020C2 (ru) 2016-04-10

Similar Documents

Publication Publication Date Title
US20190365886A1 (en) Vaccine compositions
CN111683678A (zh) 包含肺炎链球菌多糖蛋白缀合物的组合物及其使用方法
TW201622743A (zh) 免疫原醣肽、包含該醣肽之組合物及其用途
TW201110977A (en) Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
TW200823230A (en) Protein matrix vaccines and methods of making and administering such vaccines
KR20150060986A (ko) 비선형 사카라이드 컨주게이트
BR112020018974A2 (pt) Glicoconjugados de precisão como ferramentas terapêuticas
CN109078180A (zh) 用于增强免疫响应的复合物
KR102704088B1 (ko) 면역 반응 증강용 복합체의 제조 방법
US20190134177A1 (en) Conjugate for vaccination against typhoid comprising chemical conjugate of vi polysaccharide and flagellin, a process for producing the same and a composition comprising the conjugate
KR102301961B1 (ko) 아밀로이드 접합체 및 그의 용도 및 방법
AU2015215852A1 (en) Vaccine compositions
HK40117919A (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
WO2023161528A1 (en) A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
WO2025021712A1 (en) Immunogenic composition
HK40074022B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
HK40023130B (zh) 包含缀合荚膜糖抗原的免疫原性组合物及其用途
US20170119864A1 (en) Saccharide vaccine formulation
BR112018016016B1 (pt) Composição farmacêutica compreendendo um conjugado de um ou mais peptídeos cysab (33-40) (seq id no: 1) ligado à hemocianina do molusco keyhole limpet (klh), seu uso, seu método de produção, e ampola de vidro

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20121031